While most patients in the RELY and ARISTOTLE studies were at a relatively low risk for stroke, in the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) study, only 10% of the patients had CHADS-2 score less than 3 with the remainder of the patients at higher risk of stroke. Here, F10 is linked to atrial fibrillation.